News
Arcutis provides update on phase IIa clinical trial for ARQ 252 Cream as a treatment for vitiligo.
Arcutis Biotherapeutics, Inc. announced its decision to terminate the recently initiated Phase IIa clinical trial evaluating ARQ 252, a topical small molecule inhibitor of Janus kinase type 1 (JAK1), as a potential treatment for vitiligo (ARQ-252-213). Arcutis’ decision is based on further analyses of the ARQ 252 drug formulation used in both this vitiligo study and the recently completed Phase IIb study evaluating ARQ-252 for the treatment of chronic hand eczema (ARQ-252-205).
As previously announced, the Phase IIb chronic hand eczema study did not meet its primary endpoint, with none of the ARQ-252 arms achieving statistical significance versus vehicle. Further analyses of that study pointed toward inadequate local drug delivery to the skin as a key driver of the lack of efficacy.
Condition: Vitiligo
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.